Cathepsin B Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Cathepsin B is a lysosomal cysteine protease involved in protein degradation within lysosomes. It plays important roles in protein turnover, autophagy, and extracellular matrix remodeling. Cathepsin B has been studied extensively in Alzheimer's disease for its ability to degrade [amyloid-beta](/proteins/amyloid-beta) and its role in inflammatory responses. [@muellersteiner2006]
Protein Information
Structure
Signal peptide: Targets to secretory pathway
Propeptide (25 aa): Inhibits activity until processing
Mature enzyme: Catalytic domain with occluding loop
Dipeptide removal: Final activation step
Normal Function
Lysosomal protease: Degrades proteins in lysosomes
Protein turnover: Cellular protein homeostasis
[Autophagy](/entities/autophagy): Role in autophagic-lysosomal degradation
Aβ degradation: Cathepsin B can degrade [amyloid-beta](/proteins/amyloid-beta)
Dual role: May also generate Aβ fragments
Therapeutic potential: Enhancing cathepsin B activity
Expression changes: Increased in AD brain
Parkinson's Disease
Lysosomal dysfunction: Implicated in PD pathogenesis
Alpha-synuclein degradation: May degrade α-syn
GBA associations: Interactions with GBA1
Other Diseases
Cancer: Overexpression promotes tumor invasion
Arthritis: Role in cartilage degradation
Pancreatitis: Involved in tissue damage
Therapeutic Targeting
Key Publications
Hook VY, et al. (2008). Cathepsin B is a new drug target. Drug News Perspect. 21(9):470-6. https://doi.org/10.1358/dnp.2008.21.9.1272060
Mueller-Steiner S, et al. (2006). Antiamyloidogenic functions of cathepsin B. Neuron. 51(6):703-14. https://doi.org/10.1016/j.neuron.2006.07.027
Wolfe DM, et al. (2010). Autophagy failure in Alzheimer's disease. Exp Neurol. 226(2):245-53. https://doi.org/10.1016/j.expneurol.2010.08.001
Expression Pattern
Cathepsin B is expressed in various cell types throughout the brain:
[Neurons](/entities/neurons): Moderate expression in cortical and hippocampal neurons
[Microglia](/entities/microglia): High expression in activated [microglia](/cell-types/microglia), especially in disease states
[Astrocytes](/entities/astrocytes): Variable expression, increased in reactive astrocytes
Oligodendrocytes: Lower baseline expression
In the healthy brain, cathepsin B localizes primarily to lysosomes in the soma and proximal dendrites. During neurodegeneration, its subcellular distribution changes, with increased expression in dystrophic neurites surrounding amyloid plaques in AD brain.
Molecular Mechanisms
Amyloid-Beta Metabolism
Cathepsin B exhibits a complex relationship with amyloid-beta (Aβ):
Degradation: Can cleave and degrade Aβ40 and Aβ42 peptides
Generation: May generate Aβ fragments through non-canonical processing
Secretion: Released in [exosomes](/entities/exosomes) under certain conditions
Inflammation: Activates inflammatory responses through [NLRP3](/proteins/nlrp3) inflammasome
Autophagy-Lysosomal Pathway
Cathepsin B is crucial for autophagic degradation:
Maturation: Required for proper autophagosome-lysosome fusion
Activity: Optimal at acidic pH (4.5-5.5) in lysosomes
Dysfunction: Cathepsin B activity declines with aging
Inhibition: CA-074Me and other inhibitors block autophagic flux
Cell Death Pathways
Cathepsin B can initiate both apoptotic and necrotic cell death:
Extracellular release: Escapes lysosomes during cellular stress
Caspase activation: Can activate caspase-8 and caspase-3
Mitochondrial dysfunction: Induces cytochrome c release
[Necroptosis](/mechanisms/necroptosis): Associated with necroptotic cell death
Biomarker Potential
Cathepsin B has been investigated as a biomarker:
CSF levels: Elevated in AD, PD, and MCI patients
[Blood-brain barrier](/entities/blood-brain-barrier): Peripheral levels may reflect CNS pathology
Exosome markers: Detectable in neuron-derived exosomes
Therapeutic monitoring: Could track lysosomal modulation efficacy
Drug Development
Current therapeutic strategies targeting cathepsin B:
Research Directions
Key areas of ongoing research:
Target validation: Confirm cathepsin B as therapeutic target
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000100129-CTSB)
Background
The study of Cathepsin B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Hook V, Yoon M, Mosier C, et al, Cathepsin B and D in CSF: biomarkers for neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32847978/)
[Mueller-Steiner S, Zhou Y, Arai H, et al, Antiamyloidogenic and neuroprotective functions of cathepsin B (2006)](https://pubmed.ncbi.nlm.nih.gov/16982417/)
[Wang C, Tammi M, Tammi R, et al, Distribution of cathepsins B, D in human brain (1992)](https://pubmed.ncbi.nlm.nih.gov/1382019/)
[Cataldo AM, Paskevich PA, Kominami E, Nixon RA, Lysosomal system in Alzheimer disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1763010/)
[Wendt W, Zhu X, Deng HB, et al, Cathepsin D and B in brain (2004)](https://pubmed.ncbi.nlm.nih.gov/15554152/)